Clinical outcome of myelodysplastic syndrome progressing on hypomethylating agents with evolving frontline therapies: continued challenges and unmet needs

Detalles Bibliográficos
Autores principales: Ghorab, Ahmad, Al-Kali, Aref, Elliot, Michelle, Gangat, Naseema, Alkhateeb, Hasan, Shah, Mithun, Liu, Yuanhang, Yi, Cecilia Arana, Murthy, Hemant, Kharfan-Dabaja, Mohamed, Tefferi, Ayalew, Patnaik, Mrinal, Litzow, Mark, Badar, Talha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9232594/
https://www.ncbi.nlm.nih.gov/pubmed/35750664
http://dx.doi.org/10.1038/s41408-022-00691-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9232594/
https://www.ncbi.nlm.nih.gov/pubmed/35750664
http://dx.doi.org/10.1038/s41408-022-00691-9

Ejemplares similares